Navigation Links
Pharsight Hosts European PKS User Meeting
Date:5/23/2008

Second Annual European Meeting to be Held In Paris

MOUNTAIN VIEW, Calif., May 23 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that it will host its second Pharsight(R) Knowledgebase Server(TM) (PKS(TM)) European User Group Meeting on May 28 and 29, 2008 at the Hotel Concorde La Fayette, Paris, France.

The meeting provides an environment for industry scientists and developers to discuss challenges and advances in regulatory compliant PK/PD ("pharmacokinetic and pharmacodynamic") data management. Case studies will be presented by industry attendees to illustrate their use of PKS and the decisive impact the software has had on facilitating improved productivity in their drug development processes. More information is available by emailing info@pharsight.com.

"Our expanding European PKS user base has requested additional opportunities to meet and discuss developments in compliant, high-productivity PK/PD data management," said Shawn O'Connor, Pharsight president, CEO and chairman. "These meetings allow PKS users to benefit from the experience of their peers and allow Pharsight engineers to maintain close contact with our clientele."

About PKS

PKS is a high-productivity, regulatory-compliant enterprise data repository that manages clinical pharmacology data. PKS enables pharmaceutical and biotechnology companies to better manage and control preclinical and clinical PK/PD data and analyses, thus supporting higher modeling productivity as called for in the FDA's Critical Path Initiative. The FDA is using PKS under a Cooperative Research and Development Agreement (CRADA). Companies also use PKS to build PK/PD data management architecture that complies with the FDA's regulation 21 CFR Part 11, which has set new standards for computer system validation and usage. PKS is directly integrated with WinNonlin(R) Enterprise(TM), Pharsight's industry leading PK/PD modeling and analysis tool for state-of-the-art modeling and analyses, and supports direct access to any ODBC capable data source. PKS also supports analysis with leading tools such as NONMEM(R) and SAS(R).

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight, Pharsight Knoweledgebase Server, PKS, WinNonlin, and WinNonlin Enterprise are trademarks or registered trademark of Pharsight Corporation. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharsight Achieves First License Sale for Public-Source Database
2. Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007
3. Pharsight Expands Strategic Consulting Services Team
4. Pharsight Hosts Fourth Annual PKS User Group Meeting
5. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
6. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
7. Pharsight Announces 1-For-3 Reverse Stock Split
8. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
9. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
10. Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call
11. Pharsight Achieves $7.4 Million in Quarterly Revenue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives ... the award for Excellence in Volunteer Experience from US2020. , US2020’s mission is ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):